P2Y11 receptor antagonist NF340 ameliorates inflammation in human fibroblast-like synoviocytes: An implication in rheumatoid arthritis

IUBMB Life. 2019 Oct;71(10):1552-1560. doi: 10.1002/iub.2077. Epub 2019 Jul 13.

Abstract

Rheumatoid arthritis is a common chronic inflammatory joint disease. Fibroblast-like synoviocytes-mediated inflammation is closely associated with the development of rheumatoid arthritis. In this study, we report that P2Y11 receptor activity is required for cytokine-induced inflammation in primary fibroblast-like synoviocytes (FLS). P2Y11R is fairly expressed in primary FLS isolated from healthy subjects and is elevated to around three- to four-fold in rheumatoid arthritis-derived FLS. The expression of P2Y11R is inducible upon IL-1β treatment. Blockage of P2Y11R by its antagonist suppresses IL-1β-induced TNF-α and IL-6 induction and ameliorates oxidative stress as determined by levels of cellular ROS and the oxidative byproduct 4-HNE. Moreover, blockage of P2Y11R by NF340 inhibits IL-1β-induced matrix metalloproteinase protein expression as indicated by the levels of MMP-1, MMP-3, and MMP-13. Mechanistically, blockage of P2Y11R mitigates IL-1β-activated NFκB signaling, which was revealed by reduced IκBα phosphorylation, nuclear p65 accumulation, and NFκB promoter activity. Our study provides evidence of a protective mechanism of P2Y11R antagonist NF340 against cytokine-induced inflammation. Therefore, targeting P2Y11R could have potential therapeutic implication in the treatment of RA.

Keywords: IL-1β; NF340; NFκB; P2Y11 receptor (P2Y11R); fibroblast-like synoviocytes (FLS).

MeSH terms

  • Animals
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / genetics
  • Arthritis, Rheumatoid / pathology
  • Fibroblasts / drug effects
  • Gene Expression Regulation / drug effects
  • Humans
  • Inflammation / drug therapy*
  • Inflammation / genetics
  • Inflammation / pathology
  • Inflammation Mediators / pharmacology
  • Interleukin-1beta / genetics
  • Matrix Metalloproteinase 1 / genetics
  • Matrix Metalloproteinase 13 / genetics
  • Matrix Metalloproteinase 3 / genetics
  • NF-KappaB Inhibitor alpha / genetics
  • NF-kappa B / genetics
  • Oxidative Stress / drug effects
  • Phosphorylation / drug effects
  • Promoter Regions, Genetic / drug effects
  • Purinergic P2Y Receptor Antagonists / pharmacology*
  • Receptors, Purinergic P2 / drug effects
  • Receptors, Purinergic P2 / genetics*
  • Synoviocytes / drug effects

Substances

  • IL1B protein, human
  • Inflammation Mediators
  • Interleukin-1beta
  • NF-kappa B
  • P2RY11 protein, human
  • Purinergic P2Y Receptor Antagonists
  • Receptors, Purinergic P2
  • NF-KappaB Inhibitor alpha
  • Matrix Metalloproteinase 13
  • MMP3 protein, human
  • Matrix Metalloproteinase 3
  • Matrix Metalloproteinase 1